glp-1 mimetics GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes GLP-1s like semaglutide are not

Of them, chlorogenic acid is noteworthy as a lipid regulator and lipid oxidizing reduction that may be beneficial in preventing cardiovascular disease (46)

Tirzepatide is a dual-action medication that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), offering potentially stronger effects for certain users

Roche Holding AG Roche contributes through diagnostics and personalized medicine initiatives that complement GLP-1 therapy, helping optimize treatment strategies for obesity and diabetes

Device-based data does not substitute for medical evaluation, diagnosis, or provider-directed treatment

Common adverse events and side effects Tirzepatide may cause common side effects in irritable bowel syndrome, such as diarrhea, constipation, nausea, vomiting, upper abdominal discomfort, decreased appetite, and abdominal pain